Percutaneous radiofrequency ablation for patients with malignant lung tumors: a phase II prospective multicenter study (JIVROSG-0702)

Japanese Journal of Radiology

Volumn 34, Issue 8, 2016, Pages 556-563

  Gobara, Hideo ^a   Arai, Yasuaki ^b   Kobayashi, Takeshi ^c   Yamakado, Koichiro ^d   Inaba, Yoshitaka ^e   Kodama, Yoshihisa ^f   Yamagami, Takuji ^g   Sone, Miyuki ^h   Watanabe, Hirokazu ^b   Okumura, Yoshihiro ⁱ   Shinya, Takayoshi ^a   Kurihara, Hiroaki ^b   Kanazawa, Susumu ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c ISHIKAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^d MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f TEINE KEIJINKAI HOSPITAL   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

ⁱ Fukuyama City Hospital   (Japan)

Author keywords

Clinical trial; JIVROSG; Lung cancer; Multicenter; Prospective; Radiofrequency ablation

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ELECTRODE; FEMALE; FOLLOW UP; HUMAN; HYPOXIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; LUNG CANCER; LUNG FUNCTION TEST; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS RADIOFREQUENCY ABLATION; PHYSICAL EXAMINATION; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT RESPONSE; TUMOR GROWTH; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; LUNG; LUNG NEOPLASMS; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84980316441     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-016-0557-z     Document Type: Article

References (25)

1. National Cancer Center. Cancer statistics in Japan. 2015. http://www.ncc.go.jp/en/index.html. Accessed Nov 27, 2015.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
4. European Association for the Study of the Liver. European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
5. de Baère T, Palussière J, Aupèrin A, Hakime A, Abdel-Rehim M, Kind M, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology. 2006;240:587–96.
6. Gillams AR, Lees WR. Radiofrequency ablation of lung metastases: factors influencing success. Eur Radiol. 2008;18:672–7.
7. Hiraki T, Sakurai J, Tsuda T, Gobara H, Sano Y, Mukai T, et al. Risk factors for local progression after percutaneous radiofrequency ablation of lung tumors: evaluation based on a preliminary review of 342 tumors. Cancer. 2006;107:2873–80.
8. Lencioni R, Crocetti L, Cioni R, Suh R, Glenn D, Regge D, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicenter clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621–8.
9. Chua TC, Sarkar A, Saxena A, Glenn D, Zhao J, Morris DL. Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients. Ann Oncol. 2010;21:2017–22.
10. Dupuy DE, Fernando HC, Hllman S, Ng T, Tan AD, Sharma A, Rilling WS, Hong Kelvin, Putnam JB. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121:3491–8.
11. Higuchi M, Honjo H, Shigihara T, Shishido F, Suzuki H, Gotoh M. A phase II study of radiofrequency ablation therapy for thoracic malignancies with evaluation by FDG-PET. J Cancer Res Clin Oncol. 2014;140:1957–63.
12. Japan Clinical Oncology Group (JCOG). Common terminology criteria for adverse events version 3.0. 2007. http://www.jcog.jp/doctor/tool/ctcae.html. Accessed Nov 27, 2015.
13. Okuma T, Okamura T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med. 2006;20:115–21.
14. Higaki F, Okumura Y, Sato S, Hiraki T, Gobara H, Akaki S, et al. Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med. 2008;22:157–63.
15. 18F-FDG PT/CT for assessing response to radiofrequency ablation treatment in lung metastases: a multicenter prospective study. Eur J Nucl Mol Imaging. 2013;40:1817–27.
16. Deandreis D, Leboulleux S, Dromain C, Auperin A, Coulot J, Lumbroso J, et al. Role of FDG-PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology. 2011;258:270–6.
17. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20S.
18. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508.
19. Hiraki T, Tajiri N, Mimura H, Yasui K, Gobara H, Mukai T, et al. Pneumothorax, pleural effusion, and chest tube placement after radiofrequency ablation of lung tumors: incidence and risk factors. Radiology. 2006;241:275–83.
20. Yamagami T, Kato T, Hirota T, Yoshimatsu R, Matsumoto T, Nishimura T. Pneumothorax as a complication of percutaneous radiofrequency ablation for lung neoplasms. Diag Interv Radiol. 2006;17:1625–9.
21. Okuma T, Matsuoka T, Yamamoto A, Oyama Y, Toyoshima M, Nakamura K, et al. Frequency and risk factors of various complications after computed tomography-guided radiofrequency ablation of lung tumors. Cardiovasc Interv Radiol. 2008;31:122–30.
22. Hiraki T, Gobara H, Fujiwara H, Ishii H, Tomita K, Uka M, et al. Lung cancer ablation: complications. Semin Interv Radiol. 2013;30:169–75.
23. Steinke K, Sewell PE, Dupuy D, Lencioni R, Helmberger T, Kee ST, et al. Pulmonary radiofrequency ablation—an international study survey. Anticancer Res. 2004;24:339–43.
24. Kashima M, Yamakado K, Takaki H, Kodama H, Yamada T, Uraki J, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol. 2011;197:W576–80.
25. Tada A, Hiraki T, Iguchi T, Gobara H, Mimura H, Toyooka S, et al. Influence of radiofrequency ablation of lung cancer on pulmonary function. Carciovasc Interv Radiol. 2012;35:860–7.